Related Experiment Video

Updated: Jun 14, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Biological characterization of 2-aminothiazole-derived Cdk4/6 selective inhibitor in vitro and in vivo

Hiroshi Hirai1, Toshiyasu Shimomura, Makiko Kobayashi

  • 1Department of Oncology, Merck Research Laboratories, Tsukuba, Ibaraki, Japan. yrdyc661@yahoo.co.jp

Cell Cycle (Georgetown, Tex.)
|April 8, 2010
PubMed

Insights

A novel Cdk4/6 inhibitor, Compound A, effectively halts cancer cell proliferation by targeting the p16INK4a/cyclin-dependent kinase (Cdk)4, 6/Retinoblastoma (Rb) pathway. It shows promise as a targeted cancer therapy with a favorable safety profile in preclinical models.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Aberrations in the p16INK4a/cyclin-dependent kinase (Cdk)4, 6/Retinoblastoma (Rb) pathway are common in human cancers.
  • Targeting Cdk4/6 presents a promising strategy for cancer therapy.

Purpose of the Study:

  • To biologically characterize a novel 2-aminothiazole-derived selective Cdk4/6 inhibitor, Compound A.
  • To evaluate the in vitro and in vivo efficacy and safety profile of Compound A.

Main Methods:

  • In vitro kinase assays to determine selectivity.
  • Cell proliferation assays in various human cancer cell lines.
  • In vivo xenograft studies in nude rats to assess pharmacodynamic effects.
  • Pharmacokinetic and safety assessments in F344 rats.

Main Results:

  • Compound A selectively inhibited Cdk4 and Cdk6 with high potency and selectivity against other kinases.
  • Compound A induced G1 cell-cycle arrest in T98G glioma cells by inhibiting pRb phosphorylation and E2F transcription.
  • Hematological cancer cell lines were more sensitive to Compound A; Rb-negative cells were insensitive.
  • In vivo, Compound A inhibited tumor growth and proliferation markers in xenografts with minimal impact on normal intestinal cells and no immunosuppression in rats.

Conclusions:

  • Compound A demonstrates potent and selective inhibition of Cdk4/6, leading to cell-cycle arrest and anti-proliferative effects in cancer cells.
  • Selective Cdk4/6 inhibition shows a favorable therapeutic window, with reduced toxicity to normal proliferating tissues compared to pan-Cdk inhibitors.
  • Compound A represents a potential targeted therapy for cancers driven by the Rb pathway, warranting further clinical investigation.

More Related Videos

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.